Medical News Today -
31 Oct 2013 11:00
Neovasc Inc. (TSXV: NVC) has announced that a review of results from preclinical studies of its TiaraTM valve for the transcatheter treatment of mitral regurgitation has been published in JACC: Cardiovascular Interventions. The review concludes that implantation of the Tiara valve is technically feasible, safe and results in a stable and well-functioning mitral bioprosthesis...
Share this Article